Experts recently debated whether additional intensive therapy can improve posttransplant outcomes for patients with acute myeloid leukemia who have residual disease after induction therapy.
Roland Walter, MD, PhD, and Johannes Schetelig, MD, debated on the sequencing of allogeneic stem cell transplant in patients with relapsed or refractory acute myeloid leukemia.